Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). Cynata is using its proprietary Cymerus technology to produce potent, consistent mesenchymal stem cells (MSCs) at scale to address critical shortcomings in existing methods of production of MSCs () for therapeutic use. Today, we sit down with Dr. Ross Macdonald (MD & CEO) & Dr. Kilian Kelly (COO) to understand Cynata’s exciting pipeline of clinical opportunities including the planned Phase 2 trial in Graft vs. Host Disease (GvHD) which just received Investigational New Drug (IND) approval in the US.